Efficacy of Neural Prolotherapy in Treatment of Meralgia Paresthetica
NCT ID: NCT04499911
Last Updated: 2020-08-05
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
15 participants
INTERVENTIONAL
2018-04-15
2019-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The aim of the current study was to assess the efficacy of neural prolotherapy (subcutaneous perineural injection of dextrose 5% solution) on reliving pain and improvement of function and quality of life in patients with meralgia paresthetica.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy of Ultrasound-guided Injection of 5% Dextrose for Meralgia Paresthesia
NCT06251882
Effect of Different Ultrasound Doses on Median Nerve Conduction Parameters
NCT05233488
Peripheral Nerve Block in Patients With Painful Diabetic Polyneuropathy
NCT04699734
Effect of High Tone Power Therapy on Neurophysiological Measures and Function Outcome in Patients With Diabetic Neuropathy
NCT03888872
High Tone Power Therapy Versus Transcutanuoselectrical Nerve Stimulation on Polyneuropathic Pain in Diabetic Patients
NCT06822218
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Neural prolotherapy was reported to improve and relieve of neuropathic pain including that of meralgia paresthetica. Neural prolotherapy is the subcutaneous perineural injection of isotonic dextrose (5%) solution especially at the points of fascial penetration of the sensory nerve. It is the site where the sensory nerve reaches the subcutaneous plane. There are scanty studies assessed this issue.
The aim of the current study was to assess the efficacy of neural prolotherapy (subcutaneous perineural injection of dextrose 5% solution) on reliving pain and improvement of function and quality of life in patients with meralgia paresthetica.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Neural prolotherapy
Neural prolotherapy using isotonic dextrose 5% in water solution (about 5 ml). The isotonic dextrose 5% in water solution (a total volume of about 5 ml). Subcutaneous perineural injection of dextrose (5%) in sterile water was given once. The injection was administered by using the Lyftgot technique of neural prolotherapy on the lateral aspect of the thigh along the tender areas.
Isotonic dextrose 5% in water solution
The isotonic dextrose 5% in water solution (a total volume of about 5 ml). Subcutaneous perineural injection of dextrose (5%) in sterile water was given once. The injection was administered by using the Lyftgot technique of neural prolotherapy on the lateral aspect of the thigh along the tender areas.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Isotonic dextrose 5% in water solution
The isotonic dextrose 5% in water solution (a total volume of about 5 ml). Subcutaneous perineural injection of dextrose (5%) in sterile water was given once. The injection was administered by using the Lyftgot technique of neural prolotherapy on the lateral aspect of the thigh along the tender areas.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* The symptoms needed to be present for at least three months.
* The patients should be unresponsive to conservative treatment. The conservative treatment included lifestyle modification including weight reduction, activity modification (avoid the use of seat belts) and avoidance of tight underwear (tight garments such as jeans, uniforms); non-steroidal anti-inflammatory drugs and anticonvulsants for neuropathic pain; and physiotherapy.
Exclusion Criteria
* Endocrine disorders.
* Metabolic disorders.
* Systemic rheumatologic disorders.
* Neurological disorders including peripheral neuropathy, lumbar radiculopathy and lumbar plexopathy.
* Coagulopathy.
* Anticoagulant treatment.
* Current skin or soft tissue infection at or near the site of injection.
* Prior local injection of corticosteroid in the past year for meralgia paresthetica.
* Prior neural prolotherapy in the past year for meralgia paresthetica.
* Prior surgery in the affected thigh region.
* Patients presented with a systemic active inflammatory condition or infection.
* Pregnancy.
* Patients refused to participate in the study
18 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Alexandria
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Emmanuel Kamal Aziz Saba
Assistant professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Emmanuel K Saba, MD
Role: PRINCIPAL_INVESTIGATOR
Faculty of Medicine, Alexandria University, Alexandria Governorate, Egypt.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Faculty of Medicine, Alexandria University
Alexandria, , Egypt
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
0303901
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.